A Conceptual Model-Based Application for the Treatment and Management of Data in Pediatric Oncology: The Neuroblastoma Use Case

Jesús Carreño-Bolufer[1] [a], José Fabián Reyes Román[1] [b], Sergio Pérez Andrés[1] [c],
Désirée Ramal Pons[2], Víctor Juárez Vidal[1], Adela Cañete Nieto[2] [d] and Óscar Pastor[1] [e]

[1]*Valencian Research Institute for Artificial Intelligence (VRAIN), Universitat Politècnica de València, Valencia, Spain*

[2]*Grupo de Investigación Clínica y Traslacional en Cáncer, Instituto de Investigación Sanitaria La Fe (IIS La Fe),*

jecarbo@vrain.upv.es, jreyes@pros.upv.es

Keywords: ClinGenNBL, Conceptual Modeling, Neuroblastoma, Pediatric Oncology, Data Management, CMN.

Abstract: Neuroblastoma is one of the leading causes of death in childhood oncology. Current treatments for these patients are general and not targeted, including radiotherapy, chemotherapy, and surgery. There is a need for more efficient methods. Precision Medicine (PM) can help to overcome this challenge. PM incorporates clinical, lifestyle, and genomic data, among others, into a standardized process to provide individualized treatment. However, a large amount of data is needed to achieve PM, and the heterogeneity present in the case of neuroblastoma poses a challenge for integration and, consequently, for knowledge generation. We need a solid domain definition that provides a foundation for experts to work on, which implies generating a conceptual model. Based on this model, any Information System (IS) can be developed. ISs play a vital role in managing clinical data efficiently. Much of the clinical data has been captured and managed over the years with inefficient tools such as spreadsheets. In this work, we first present the new Conceptual Model of Neuroblastoma (CMN), with a special focus on genomics, and second, ClinGenNBL, a conceptual model-based web application that implement the CMN with the goal of assisting clinicians in managing patients with neuroblastoma through a user-friendly interface.

In Memoriam and in honor of the beloved Victoria Castel Sánchez, who passed away during the research and publication of this research work.

1 INTRODUCTION

The most frequent tumors in Spain (0-14 years, between 2010-2023) are leukemias 28.1%; lymphomas 12.1% and central nervous system tumors 24.8% (Cañete Nieto et al., 2023). The Neuroblastoma (NBL), or secondary nervous system tumor, with 7.7% of cases, comes in fourth place in terms of incidence. NBL is also the most frequent solid extracranial tumor in childhood (Castleberry, 1997). In the United States, it represents 6% of all pediatric cancers, with a survival rate of 82% for ages from birth to 14 years old (Siegel et al., 2024).

In light of this problem, the Spanish NBL Group of SEHOP[1] was created in 1987, led by the Pediatric Oncology Unit of Hospital Universitari i Politècnic La Fe (HUP/IIS LaFe) (HUPLF). Since then, the group has developed and fine-tuned therapeutic and diagnostic protocols for NBLs and participated in international groups with SIOPEN[2] and ANRA[3]. They have also produced a wide variety of reports and disseminated study results (Cañete Nieto et al., 2023)

We encounter massive amounts of data from which knowledge could be generated to advance Precision Medicine (PM) (McCabe et al., 2024) (Ca-

---

[a] https://orcid.org/0009-0006-4720-4037
[b] https://orcid.org/0000-0002-9598-1301
[c] https://orcid.org/0000-0002-9316-210X
[d] https://orcid.org/0000-0002-5669-5097
[e] https://orcid.org/0000-0002-1320-8471

[1]Sociedad Española de Hematología y Oncología Pediátricas. https://www.sehop.org/

[2]International Society of Paediatric Oncology European Neuroblastoma. https://www.siopen-r-net.org/

[3]Advances in Neuroblastom Research Association. https://www.anrmeeting.org/

15

haney et al., 2022). This data can help us understand patients who suffer from NBL. PM aims to provide personalized treatment for each patient. Currently, implementing PM in clinical data management requires a high investment of resources, mainly due to the complexity of the data and the lack of efficient Information Systems (IS). Each disease is unique and requires specialized tools.

Fortunately, technological advances in Software Engineering (SE) in recent years have created many ISs for better information management in different contexts (Evans, 2016). In particular, in the context of PM, these ISs play a fundamental role in managing patient follow-up and conducting studies on data collected in the clinical context over the years.

However, when applied to NBL, one of the main challenges in building an IS is the data heterogeneity in this field. Consequently, there is a lack of integrated information from a holistic perspective, which hinders the development of automated pipelines for identifying and analyzing relevant statistical data (Digital Transition,). A standard conceptual model would facilitate the integration process from diverse sources (Trujillo et al., 2018)(Cañete et al., 2022).

In summary, data management in this context presents the following problems: high heterogeneity and dispersion of data and lack of efficient mechanisms. To overcome these challenges, the following goals are specified:

1. We aim to generate a Conceptual Model (CM) to provide a common ontological framework for discussions with experts, increasing our understanding of the neuroblastoma (NBL) domain. This model will also serve as a foundation for developing an Information System (IS) to improve data management and integration, encompassing not only clinical data but also genomic data. To achieve this, we establish a shared view of the study domain, which must be supported by clinical experts.

2. To design and develop an IS based on the defined CM. This IS will improve the integration and management of the existing data in the NBL domain. It will also help clinical experts to improve their decision-making.

To achieve these goals, this work contributes to version 2.0 (V2) of the Conceptual Model of Neuroblastoma (CMN) upon which a software platform, ClinGenNBL, is implemented. ClinGenNBL, a conceptual model-based web application, serves as a work tool for clinicians, combining the management and analysis of clinical data.

The rest of the article is organized as follows: in Section 2, we provide context for the project and re-

view how information systems (IS) have been applied to improve clinical and genomic data management. Section 3, we detail the CMN, the conceptual model that defines the NBL domain as the result of meetings with experts in the field. Section 4 presents the result of integrating the CMN with the Conceptual Model of the Human Genome (CMHG) to expand the genetic component and support the advancements in the field of the PM. In Section 5, we introduce ClinGenNBL, an IS for clinical data management based on the CMN. Finally, Section 6 concludes the article with the contribution of this work and outlines future lines of research.

2 PREVIOUS AND RELATED WORK

This section provides context for understanding the work carried out by presenting the background on which this work is based in Section 2.1 and a summary of related works in Section 2.2.

2.1 Previous Work

The project of this work started in 2018, with the first version (V1) of the CMN proposed by Arevshatyan, Reyes Roman(co-author) and collaborators (Arevshatyan et al., 2019), defining the domain. Their work highlighted the importance of building a Genomic Information System (GeIS) upon a conceptual model. Later, in 2020, the CMN was improved (V1.5), and the first version of the IS based on this model was designed and developed (Arevshatyan et al., 2020). It was adapted to the needs of the Pediatric Oncology department of the HUPLF.

The clinical staff of the HUPLF used the prototype to store patient data, diagnostic evaluations, and treatments. However, this prototype has become obsolete due to the lack of maintenance and the new needs of the clinical staff. Most of the technologies used in the prototype (jQuery, Bootstrap, Jasmine-Express) are no longer maintained or have been replaced by new ones. Moreover, the prototype does not have a responsive design and has a lot of inconsistencies in its user interfaces.

In recent years, new technologies have emerged that facilitate development and maintenance. This analysis, part of the work associated with this research, culminated in a technical report that provides a comprehensive analysis (Fernández García et al., 2022). Rather than attempting to fix all the prototype's flaws, a new version of the IS will be developed, incorporating best practices of modern tech-

nologies and based on an updated version of the CMN.

Therefore, this work aims to generate the V2 of the CMN using conceptual modeling techniques, as they allow for an improved understanding of the domain and facilitate the treatment of complex data, such as those about NBL. Based on this CMN, we design and develop a new version of the IS, ClinGenNBL, that adapts to the new requirements demanded by the clinical staff. Finally, the resulting IS must be implemented with novel but stable technologies to improve the development and maintenance time.

2.2 Related Work

In order to develop a better solution, an analysis of research related to this research work has been carried out. This section presents several works that belong to the context of bioinformatics and/or aim to design and develop an IS based on conceptual models. One of the areas where the use of conceptual models has been most influential is in the human genome. Since the contribution by Paton (Paton et al., 2000), which introduced a collection of genomic (i.e., implementation-independent) conceptual data models for genomic data. These conceptual models are amenable to (more or less direct) implementation on different computing platforms.

Following the above work, numerous papers applying conceptual modeling techniques emerged. An example of this is the work of Martin et. al., whose goal is to design and develop an IS that integrates human genome variant data from different sources (Martin and Celma, 2011). To achieve this goal, the definition and categorization of variations is unified through conceptualization. Once the conceptual model was established, a database (Human Genome Data Base, HGDB) was implemented.

In the Ph.D. thesis of Burriel Coll (Burriel Coll, 2017), the aim is to solve the problem of heterogeneity and dispersion of genomic data on breast cancer. Within this domain, the biggest challenge is the treatment of a high volume of data, as it faces a disease with high prevalence. It aims to analyze the information available in the databases and integrate it into an IS, thanks to creating a CM.

Focusing the context on genomics, Bernasconi et. al. present an article that proposes a conceptual model of genomic metadata, whose purpose is to favor queries to experimental databases. Their work can be divided into three phases. The first phase analyzes the attributes of genomic metadata. The second phase uses an up-bottom method to build the in-tegrated schema. The last phase corresponds to validating the conceptual model with different databases (Bernasconi et al., 2017).

The doctoral thesis of Reyes Román (2018) defines a framework focused on using CM. It proposes to use an CMHG as a fundamental basis for generating Genomic Information Systems (GeIS), intending to facilitate a conceptualization of the domain that allows to reach accurate knowledge and to be able to reach PM (Reyes Román and Pastor, 2018). Within the context of NBL is the work of Arevshatyan, which analyzes and integrates clinical and genomic data. It highlights that a Genomic IS based on a conceptual model allows for improved adaptation to new domain requirements. It also greatly simplifies the integration and management of heterogeneous and homogeneous data (Arevshatyan et al., 2019). Within a broader clinical context (not only NBL), Arevshatyan et. al. present a practical experience of data analysis and decision-making process where a CM is designed to develop an IS to manage clinical, pathological, and molecular data in an integrated manner in the oncology department of two hospitals (Arevshatyan et al., 2020).

As a result of the COVID-19 disease, numerous databases were created to mitigate the effects of the pandemic. Within this context, Bernasconi et. al. reviews the data integration efforts needed to access and search SARSCoV2 genome sequences and metadata deposited in the most important viral sequence repositories (Bernasconi et al., 2020). The paper applies conceptual modeling techniques to structure and organize the information.

Finally, the work of Garcia et. al. faces the challenge of integrating a huge amount of existing omic data (García Simón et al., 2021). To this end, conceptual modeling techniques are applied to facilitate understanding, communication, and problem-solving in the domain while establishing a common ontological framework to stimulate the communication and evolution of complex domain knowledge. The work's main contribution is the presentation of the Genome Conceptual Schema, independent of the species, which allows the representation of proteomic data and facilitates their integration.

3 CONCEPTUAL MODEL OF NEUROBLASTOMA (CMN)

Conceptual Modeling (CM) is a technique used to understand a problem domain and communicate effectively with users and subject matter experts. It has been beneficial in homogenizing data in the clinical

context, as discussed in Section 2.2. In this section, we present the V2 of the Conceptual Model of Neuroblastoma (CMN).

Figure 1 shows the CMN resulting from the domain study and collaborative meetings with clinical experts at HUPLF. We conducted a preliminary literature review and did not find any other conceptual models specifically addressing the neuroblastoma domain. Based on a previous CMN (Arevshatyan et al., 2020), the analysis of each of the classes has been carried out, structured in views, and extended to adapt it to the new knowledge of the domain. Then, the model is proposed to represent all the procedures performed by the clinical staff throughout all the stages of patient care.

The different views of the model shown in Figure 1 are discussed below:

- Patient View: It contains all demographic and general information about the patient, including their status throughout the course of the disease.

- Episode View: Encompasses all services provided to the patient with the medical problem within a specific period of time. This view includes the protocol to which these services belong and all information regarding symptoms, tumors, and metastases.

- Treatment View: Represents all possible treatments the patient can have. The subclasses represent the special types of treatments the patient receives depending on the type of stage and how it progresses.

- Test view: Represents the various diagnostic tests physicians perform to detect and diagnose the disease.

- Genetic View: Contains all the genomic information about the patient obtained through the performance of genetic tests.

The Patient View is composed of all necessary patient data. It has been placed at the top as the rest of the views depend on the existence of the patients. Before creating any patient, we must have at least one "Hospital" in the system.

Once this requirement is fulfilled, it is possible to start registering patients who belong to the class "Patient". This will occur on the first visit to the hospital center, where the basic patient data, such as name, date of birth, gender, weight, height, etc., will be taken.

In addition to the basic data, every patient should have a history of conditions over time. This history is represented by the class "Status". A patient may be alive, either with a tumor, "AliveWithTumor" or without it, class "AliveFreeDisease", and have local relapses or metastases in the course of its evolution, in which case it will be necessary to indicate its type, included in the class "Relapse", or mark the disease progression as death cause, represented by the class "Deceased".

The Episode View is the central pillar of the model and around which all other views revolve. In the hierarchy of views presented in Figure 1, it is in the center, not just by chance, as the patient's evolution is related to the episodes. This is the one in charge of keeping the history of diagnostic tests, treatments, symptoms, etc.

Each time the patient is evaluated or receives any treatment, an episode is created in the system. This episode can be of a special type called a diagnosis, manifested in the diagram with the class "Diagnosis", which represents the event for which the patient first goes to the hospital and the NBL diagnosis process begins.

At the beginning of his assessment, the application user will introduce the patient's symptoms, represented in the CMN by the class "Symptom", through a description and a date of the different symptoms of the patient.

When diagnosing the patient, a primary tumor, described by the class "Tumor", must be added. The application user will specify the tumor's type, location, size, and date for each tumor. If a metastasis is detected in a patient, it will be reflected through the entity with that name and which contains the attributes of type and date.

The episodes will be associated with a certain phase, identified as "Phase" in the model, corresponding to a protocol called "Protocol" in the model. A medical protocol is a set of recommendations on the diagnostic procedures to be used for any patient with a given clinical condition. Or on the most appropriate therapeutic approach to a clinical diagnosis or health problem (UNITECO, 2019). Each patient receives treatment based on a single protocol. These have a duration and are renewed over the years.

Once the patient's main data have been entered, several diagnostic tests are performed to determine the patient's stage, making it possible to establish with greater precision the treatment that the patient will receive.

Imaging methods, represented by the class "Radiological", store all relevant data from tests such as X-rays, ultrasound scans, and CT scans. Nuclear medicine encompasses information on two tests in each entity and is represented by the class "Nuclear". The different laboratory tests that can collect information on the blood or urine tests performed on the

Figure 1: Conceptual Model of NBL.

patient are represented in the class Biological. The study of audiometry tests, represented by the class with the same name "Audiometries" and the assessment of minimal residual disease (class "Minimal-Residual"), which stores the result of different tests performed on the patient.

Histological tests correspond to those tests that use a histological technique. This is the series of or-

dered steps that prepare the tissue for observation under the microscope (Guerrero Alquicira et al., 2017). These tests include:

- Bone marrow evaluation, represented by the class "HistologicalMarrow", a test that records the method or technique used, its status, whether it has been positive or not, and whether it has been evaluable or not.

- Tumoral evaluation, represented by the class "HistologicalTumor", it stores genetic information following a study on genetic information after a study has been performed on a tumor sample. Such a study can generate instances of the class "GeneticTest", which will be accompanied by a result represented by the class "GeneticResult".

Finally, clinicians will rely on genetic testing, which studies the different variants of the patient. These types of tests are studies on genes and chromosomes, represented as "Gene" and "Chromosome", which are divided into various tests, such as the study of the amplifications of a gene, represented by "Amplification", its possible variants that appear in the classes "CNV" and "Segmental" and, finally, the mutations of the gene, represented by "Mutation".

Once the protocol to be followed for the patient has been decided based on all the diagnostic tests, it is the turn of the treatments, whose basic information (date on which they were applied, the reason, the protocol to which they belong, and whether or not there were any complications, etc.) is available in the class "Treatments". The treatments will always be specific, i.e., they will always belong to surgery (class "Surgery"), chemotherapy (class "Chemotherapy"), autologous transplant (class "TransplantAut"), radiotherapy (class "Radiotherapy"), or "MIBG".

Each treatment may cause different toxicity in the patient (cardiac, nausea/vomiting, fever, infection, etc.). For this reason, it is decided to represent the different types of toxicities that may arise from each treatment by the class "Toxicity", specifying the type using its derivatives. In addition, toxicities can have a degree and a specific description, represented by the class "CtcGrade".

In summary, this section has described V2 of CMN, supported by clinical experts at HUPLF. It includes several views for patients, episodes, treatments, tests, and genetics, providing a base to manage clinical data for neuroblastoma in common terms. However, the genetic component can still be extended with other conceptual models. This task is done in Section 4. Numerous model-based applications can be built upon the CMN, for example, ClinGenNBL (Section 5).

4 INTEGRATION OF THE CONCEPTUAL MODEL OF NEUROBLASTOMA (CMN) AND THE CONCEPTUAL MODEL OF HUMAN GENOME (CMHG)

As exposed in Section 1, PM is the pathway to effectively and efficiently treat individuals suffering from NBL. It consists of applying special treatments depending on the characteristics of the patient. In this context, DNA is what defines humans the most. To this end, we focus on the genetic component of the CMN by integrating the CMN with the Conceptual Model of Human Genome (CMHG), which we detail in this section.

The CMHG used is version 2 from the thesis of Reyes Román, which features a chromosome-centered view (Reyes Román and Pastor, 2018). Below is a summary of the objectives of each view corresponding to the CMHG, which will be incorporated into the CMN presented previously in this work (Section 3) and that will give rise to the new model, CMN-CMHG.

- Structural View: As its name indicates, it describes the structure of the genome.

- Transcript View: Shows the components and concepts related to protein synthesis.

- Variation View: Models the knowledge related to the differences found in the DNA sequences of different individuals.

- Phenotype View: Represents the phenotypes associated with one or several DNA variations. The phenotype is the set of physical, biochemical, and behavioral characteristics that can be observed.

- Bibliographic View: View provides information about the data sources from which the data to be stored in the model has been extracted.

- Pathway View: Composition of processes composed of chemical reactions that take place inside a cell.

The CMN-CMHG integration can be found here[4]. In the model presented, we find three types of colors that allow us to quickly and efficiently distinguish the different parts where integration occurs. Blue marks the existing classes in both models. Purple represents the existing classes in the CMN that the inclusion of the new model has modified. Finally, green represents

---

[4]https://doi.org/10.5281/zenodo.13152470

the new connection classes, i.e. the first point of contact between the CMN and the CMHG.

The following subsections provide a detailed explanation of how the integration took place. Some views of the CMHG presented intersect with the Genetic View in the CMN, leading to segregation of this view (Subsection 4.1), while others introduce new knowledge to the CMN (Subsection 4.2).

4.1 Extension of Knowledge: Segregation of the Genetic View

All genetic information is grouped under the Genetic View in the CMN. When this view is compared with the CMHG for the first time, it is divided into four new views: the Variation View, Structural View, Transcription View, and Bibliographic View, using the same names as in the CMHG.

The first new view comes from the variations, represented by the "Variation" class in both models. This class becomes the main class of the new Variation View by adding the attributes provided by the CMHG (clinical importance, private, and version of creation). In addition to this class, the inheritance hierarchy of the classes is maintained in both models.

The contribution on the Variation View with a higher knowledge value is the extension of structural polymorphic variants. Represented by the "Structural" class in the CMN, is replaced by the class "SNP" (Single Nucleotide Polymorphism) of the CMHG. This renaming is closely related to data storage, e.g. the use of dbSNP (Sherry et al., 2001).

Continuing with the segregation of the Genetic View, the second new view is the Structural View, derived from chromosomes. The "Chromosome" class is the core around which the CMHG revolves. The "Chromosome" class now includes the sequence attribute. Additionally, the "Species" class has been included to determine the family to which each chromosome belongs; the points in the sequence where recombinations occur, represented by the "Hotspot" class; and the cytogenetic bands, represented by the "Cytoban" class, which provide characteristics of the chromosome and are, in turn, related to the imprecise subtype of the variant, in the "Imprecise" class.

In the Structural View, special attention is given to the elements of a chromosome. Where there was previously a direct connection between chromosomes and genes, the model is now enriched with transcribable elements, conserved regions, and regulatory elements. All information related to the regions is concentrated in the Transcription View, the third new view.

Of the three types of elements, special attention is given to the transceptors, represented by the class "TranscriptableElment" whose purpose is to represent a region of DNA that can be transcribed. In turn, these regions can be specialized into two types:

1. Gene: a concept that we find in the CMN enriched with new attributes, and more specifically, biotype determines the specialization of the various types of genes. of genes.

2. Exon: each of the transcribable elements that form part of the gene.

The relationship between these two classes is made through the transcripts, i.e. the "Transcript" class represents the different transcripts present in a gene and comprises a series of exons.

Finally, we find the last new view, the Bibliographic View. Similarly to what occurred in the CMN, this view provides information about the source of the data, meaning where the information to be stored in the model has been obtained. It retains the data source, represented by the "DataBank" class, its version ("DataBankVersion" class), and the relationship between genes and the data source, shown in the "ElementDataBank" class. Notably, this element's relationship has changed from the Gene class to its predecessor, "ChromosomeElement".

4.2 New Knowledge: Phenotype and Pathway

During the integration process, entirely new views were identified, meaning any element of the CMN did not represent them. Therefore, the introduction of these new views will provide previously unavailable knowledge.

One of the most important contributions made in the model's V2 extension was the inclusion of the Phenotype View. The phenotype results from genes that can be expressed and the external factors that affect their expression: environmental, nutritional, and chemical factors.

This contribution, introduced in the context of NBL, will endow the model with a combined genotype-phenotype perspective within diagnostic evaluations. This means that the model can represent phenotypic expressions for a patient.

Just as in the CMN we find parts unaffected by integration, there is the list of metabolic pathways. A metabolic pathway ("Pathway" class) is a succession of chemical reactions that take place inside the cell.

In summary, in this section, we have presented the integration of the CMN and the CMHG into a unified framework (CMN-CMHG), with an expanded genetic view that can serve as a common language

for communication in the domain of genetic Precision Medicine (PM) applied to neuroblastoma (NBL). It includes information on chromosomes, variations, phenotypes, bibliographic data, and pathways, among other elements. This integration also facilitates interoperability between different PM and NBL tools, offering deeper insights into the field.

5 CLINGENNBL: A CMN-BASED APPLICATION

This section introduces ClinGenNBL, the solution generated based on the conceptual model defined in Section 3. On the one hand, this CM has helped improve communication between the various multidisciplinary experts during the requirements definition. On the other hand, it has served as ontological support in creating software solutions developed with innovative technologies and great support from the SE community. All this is to provide an IS that responds to the needs of clinical experts in NBL and has an appropriate degree of maturity for its application in medical practice. This section describes the solution designed, developed, and validated. It also presents several screenshots from extensive use involving more than 800 real patients.

5.1 Requirements

The first phase of the solution design consisted of gathering the functional needs from the requirements analysis sessions conducted with the HUPLF clinical experts. The functional and non-functional requirements were analyzed and converted to small pieces of information using the use case analysis. ClinGenNBL allows doctors to manage and analyze the clinical data associated with NBL with a user-friendly interface. As introduced in this section, it is based on the CMN; however, some concepts are not part of the requirements as they are not needed by the experts at the time of the writing of this article.

Among its features, the data analytics section should be noted, which includes the following capabilities: i) Generate a patient state report in CSV format, ii) Search neuroblastoma hospitals by allowing the user to search for hospitals, iii) Filter neuroblastoma protocols and hospitals by any property, iv) Show the analysis of distributions in which patients are found (INRG[5] or INSS[6]) and the number of patients associated with each status, v) Display the chro-

---

[5] International Neuroblastoma Risk Group.

[6] International Neuroblastoma Staging System.

mosome alteration analysis in a table composed of patient names, applied protocol, date of birth and diagnosis, INSS, as well as Del1p[7], vi) Show gene amplification analysis composed of patient names, protocol applied, date of birth and diagnosis, INSS, as well as copies of the MYCN gene.

More information about the requirements can be found in the following technical report (Fernández García et al., 2022) (Spanish), which includes comprehensive documentation covering all the information, parameters, and options managed by the developed system. During the design of an application interface, mockups are common, which allow us to present a possible approach to the final design.

5.2 Architecture

To ensure that an IS meets the needs of stakeholders and has the necessary level of maturity for a medical application, technologies that are widely used in the software development industry and that receive the support and backing of very important companies at a professional level have been used.

ClinGenNBL consists of three components: frontend, backend, and database. By decoupling the logic and model (backend) from the view (frontend), we achieve greater flexibility and increased productivity as we get a greater separation or composition of the application. Figure 2 shows the architecture represented in a UML component diagram. Below, the components are detailed:

1. Backend: NodeJS has been used as the JavaScript execution platform. This level of abstraction aims to provide an interface, usually an API, which allows easier interaction with the database or other external services.

2. Frontend: It consists of the user interface defined in ReactJS, coded in a proprietary language called JSX, an extension of the JavaScript programming language. Other libraries, such as i18n, have been used as well. It was decided to use React as the main tool for client-side development since it is one of the most widely used web development libraries today. This component interacts with the backend through a REST API, which uses the HTTP protocol and exchanges messages in JSON format.

3. Database: Object-Relational Mapping (ORM) has been used, a technique that allows the manipulation of database data using an object-oriented

---

[7] Genetic deletion affecting the short arm of chromosome 1.

paradigm. In this case, it was decided to use Sequelize[8], a library written in TypeScript for Node.js, which allows the definition of models and relationships, the database query and the handling of these models in the form of objects. In addition, this library is compatible with many DBMSs, including MySQL8[9], which has been chosen to store all the data related to the application since it is a very mature system used throughout the history of software application development.

5.3 Validation

Validating the solution means justifying that it would contribute to the stakeholders' objectives if implemented. In the Engineering Cycle (EC), validation is performed before implementation. It involves investigating the effects of the interaction between an artifact prototype and the problem model, always comparing them with the solution requirements (Wieringa, 2014).

Expert opinion is one of the simplest ways to validate the solution (Wieringa, 2014). The design of the solution is submitted to a committee of experts, in this case, different physicians and doctors from the Clinical and Translational Research Group in Cancer (GICT-Cancer) of the HUPLF/IIS La Fe, who imagine how it will interact with the context problem (NBL data management) and try to predict the effects they think the solution will have.

The main objectives of these meetings are: i) to obtain the maximum knowledge of the domain and the research problem and ii) to consolidate and validate the progress on developing the solution. The first meetings held by the HUPLF team of experts focused on defining the requirements and studying the problems they were facing daily. Once analyzed, prioritized, and classified, they were shared along with the conceptual model with the team to validate them. The rest of the meetings that were agreed upon with the group focused on reviewing the application's progress through demonstrations. Each of them had a deliverable associated with the progress of the functionalities implemented since the previous meeting. Finally, to test the final developed software, the expert opinion exercise was divided into two stages: i) User observation and ii) User interviews.

In the user observation phase, the experts of the HUPLF were asked to perform a set of predefined tasks within the developed IS. The tasks that were

defined following the application requirements included.

- Hospital registration: The user must register a new hospital, display the list of existing hospitals, and search for the new hospital by two criteria "Name" and "City".

- Registration and protocol query: The user must register a new protocol, display the list of existing protocols, and add the different phases that make up the protocol.

- Patient registration: The user must register a new patient, display the list of existing patients, and search for the new patient by MRN[10].

- Symptom, tumor, metastasis registration: The user must register a new symptom, tumor, and metastasis on the previously created patient.

- Diagnostic evaluation registration: The user must register at least once for each of the different types of diagnostic evaluations.

- Treatment Discharge: The user must discharge at least once each treatment, including all types of toxicity.

- Consultation of patient information: The user must display the data entered in the previous tasks.

- Correction of patient errors: The user will have to edit one of the attributes of each entity and finally delete them.

The objective of the user interview is to know the user's opinion regarding the use of the application after performing the previously defined tasks. The comments can be summarized in four relevant points:

- Improvement of daily work: Using the IS during patient diagnosis and treatment allows them to offer better care and achieve Precision Medicine or Personalized Medicine. In addition, the IS allows them to perform more efficient and effective queries on patient data, speeding up the data exploitation process.

- The tool is easy to use: Team members found the application easy to use, as they could recognize and locate most of the tasks they were asked to perform without assistance.

- Stakeholders' objectives are met: The team of experts expressed that they were very satisfied with the application. They indicated that the data management would help improve the treatment provided to patients, as they would be able to analyze and extract all the data.

---

[8]Sequelize. https://sequelize.org/

[9]MySQL. https://www.mysql.com/

---

[10]Medical Record Number.

Figure 2: Solution architecture.

Figure 3: Screenshot of ClinGenNBL: Sumamry.

- Possible improvements to the application to facilitate its use were identified: The team of clinical experts suggested possible visual improvements that would facilitate the process when entering data: the grouping of certain toxicities and the creation of shortcuts in the creation of lookup tables.

In general, stakeholders reported that the use of the application was beneficial. The tool allows them to achieve their goals and improve the treatment of NBL easily and intuitively. They also mentioned that adopting the tool would take little time and could be extended to more hospitals.

In conclusion, homogenizing data related to NBL treatment and its access through a common IS produces greater satisfaction and benefits than manual and dispersed treatment (through different applications). The validation has provided encouraging findings, but the results should be studied further.

5.4 Using ClinGenNBL

Thanks to the extensive knowledge of experts in various areas relevant to this work, such as Information Systems Engineering (ISE), Bioinformatics, and Web Engineering, among others, it has been possible to achieve a high degree of maturity (TRL5 (European Comission, 2014)) in both the initial design and the final result of the application. It is ready to be transferred to HUPLF. We present several screenshots of the platform (Figures 3 and 4) and a demonstration video, where 831 real patients with relevant data were introduced. The demonstration can be found here[11].


[11]https://doi.org/10.5281/zenodo.13138339

Figure 4: Screenshot of ClinGenNBL: Manage Patient.

All the clinical data was entered in compliance with GDRP[12] legislation (GDRP, 2016).

6 CONCLUSIONS

Finally, to conclude, Section 6.1 summarizes the contribution of this work to the defined goals.

6.1 Contribution

This research aimed to generate a conceptual model for the neuroblastoma domain and to implement an information system (IS) based on it, using conceptual modeling techniques to address the identified problems. This work has contributed to the development of the V2 of the CMN and the implementation of robust software based on it (ClinGenNBL). Clinical experts continuously validate this solution at a technical and functional level. Additionally, it has highlighted the genetic aspects of the domain to advance precision medicine through the integration of CMN and CMHG.

Firstly, the CMN improves the understanding of the domain and establishes a solid foundation on which to build the solution design. The knowledge obtained from the domain study can be integrated and centralized. It also improves stakeholder communication, which is very useful during the requirements gathering and validation phase. Secondly, ClinGenNBL serves as an information system instance of

---

[12]General Data Protection Regulation.

the CMN and provides greater efficiency to the clinicians at HUPLF in managing clinical data and generating knowledge about neuroblastoma. It comprises two independent components implemented with modern and consolidated technologies such as NodeJS, React, and MySQL. Experts have successfully validated and tested it with more than 800 real patient cases.

6.2 Future Work

CMN has been developed to a stable version (V2), and ClinGenNBL has reached a high degree of maturity (TRL5). However, there is still more work to be done. Future work includes:

- Maintenance and evolution of the application: The initial application has been validated satisfactorily with the expert opinion of the HUPLF doctors. Based on the needs detected and the possible improvements identified, future developments are proposed to address new functionalities for the application.

- Implementation of the integration of the CMN-CMHG: Given the knowledge gathered throughout the work, the integration between both models (CMN and CMHG) is proposed in Section 4 but not implemented in the application. However, the integration design and development could be part of a future engineering cycle.

- Implementation of the tool in the real working environment: The next step for a successful evolution is using the application in a realistic environment. To this end, implementing the HUPLF is

only the first step, with the possibility of taking the IS to the rest of the national hospitals and expanding internationally. This must be done in collaboration with the technical service of each department in order to follow the protocols established by the healthcare organization.

ACKNOWLEDGEMENTS

REFERENCES

Arevshatyan, S. et al. (2019). Integration and analysis of clinical and genomic data of neuroblastoma applying conceptual modeling. *IEEE Journal of Biomedical and Health Informatics*.

Arevshatyan, S. et al. (2020). An application of an ehr based on conceptual modeling to integrate clinical and genomic data and guide therapeutic strategy. *ANALES*.

Bernasconi, A., Canakoglu, A., Masseroli, M., Pinoli, P., and Ceri, S. (2020). A review on viral data sources and search systems for perspective mitigation of covid-19. *Briefings in Bioinformatics*, 22(2):664–675.

Bernasconi, A. et al. (2017). Conceptual modeling for genomics: Building an integrated repository of open data. In *Conceptual Modeling*, pages 325–339, Cham. Springer International Publishing.

Burriel Coll, V. (2017). Diseño y Desarrollo de un Sistema de Información para la Gestión de Información sobre Cáncer de Mama. Universitat Politècnica de València.

Cahaney, C., Dhir, A., and Ghosh, T. (2022). Role of precision medicine in pediatric oncology. *Pediatric Annals*, 51(1):e8–e14.

Castleberry, R. P. (1997). Neuroblastoma. *Eur J Cancer*, 33(9):1430–7; discussion 1437–8.

Cañete, A. et al. (2022). Neuroblastoma in spain: Linking the national clinical database and epidemiological registries – a study by the joint action on rare cancers. *Cancer Epidemiology*, 78:102145.

Cañete Nieto, A. et al. (2023). *Cáncer infantil en España. Estadísticas 1980-2023. Registro Español de Tumores Infantiles (RETI-SEHOP)*. Universitat de València, Valencia.

Digital Transition. The digital transition in healthcare: An urgent need. En línea. Available at: https://digitalforeurope.eu/the-digital-transition-in-healthcare-an-urgent-need?lang=en. Last access: 28 of October 2024.

European Comission (2014). Technology readdiness levels. European Commission Decision C (2014)4995 of 22 July 2014). Online. Available at: https://ec.europa.eu.

Evans, R. S. (2016). Electronic health records: Then, now, and in the future. *Yearbook of Medical Informatics*, 25(S 01):S48–S61.

Fernández García, F., Reyes Román, J. F., Baghiu, C.-B., Pérez, S., and Pastor López, O. (2022). Clingennbl (v2): Integration and analysis of neuroblastoma clinical and genomic data. Available at: http://hdl.handle.net.

García Simón, A., Palacio León, A., Reyes Román, J. F., Casamayor Ródenas, J. C., and Pastor, O. (2021). A conceptual model-based approach to improve the representation and management of omics data in precision medicine. *IEEE Access*, 9:154071–154085.

GDRP (2016). Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Online.

Guerrero Alquicira, R., Rojas Lemus, M., and Fortoul van der Goes, T. (2017). *Histología y biología celular*. MCGRAW-HILL.

Martin, A. and Celma, M. (2011). Integrating human genome variation data: An information system approach. In *22nd International Workshop on Database and Expert Systems Applications*, pages 65–69.

McCabe, M. G. et al. (2024). Precision medicine for childhood cancer: Current limitations and future perspectives. *JCO Precision Oncology*, 8(8):e2300117. PMID: 38207228.

Paton, N. et al. (2000). Conceptual modelling of genomic information. *Bioinformatics*, 16(6):458–557.

Reyes Román, J. F. and Pastor, O. (2018). *Diseño y desarrollo de un sistema de información genómica basado en un modelo conceptual holístico del genoma humano*. PhD thesis, Universitat Politècnica de València.

Sherry, S. T., Ward, M.-H., Kholodov, M., Baker, J., Phan, L., Smigielski, E. M., and Sirotkin, K. (2001). dbSNP: the NCBI database of genetic variation. *Nucleic Acids Research*, 29(1):308–311.

Siegel, R. L., Giaquinto, A. N., and Jemal, A. (2024). Cancer statistics, 2024. *CA: A Cancer Journal for Clinicians*, 74(1):12–49.

Trujillo, J. C. et al., editors (2018). *Conceptual Modeling: 37th International Conference, ER 2018, Proceedings*. Springer International Publishing.

UNITECO (2019). ¿Qué son los protocolos médicsos? Available at: https://www.unitecoprofesional.es.

Wieringa, R. J. (2014). *Design Science Methodology for Information Systems and Software Engineering*. Springer.